Intra-Cellular Therapies, Inc. Securities Litigation
On or around 11/02/2017 (Stipulation and order of dismissal (voluntary dismissal))
Filing Date: May 12, 2017
According to the law firm press release, the lawsuit alleges throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) findings related to toxicity in animals treated with lumateperone (ITI-007) were observed; (2) these findings posed an additional safety concern regarding lumateperone; and (3) as a result, Intra-Cellular Therapies’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
On July 31, 2017, the Court issued an Order consolidating cases, appointing Lead Plaintiff, and approving Lead Counsel.
On September 20, 2017, Lead Plaintiffs filed a stipulation to voluntarily dismiss this action without prejudice.
Company & Securities Information
Defendant: Intra-Cellular Therapies, Inc.
Industry: Biotechnology & Drugs
Headquarters: United States
Ticker Symbol: ITCI
Company Market: NASDAQ
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Kevin Yoo, et al. v. Intra-Cellular Therapies, Inc., et al.